Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

J Urol. 2005 Dec;174(6):2422-3. doi: 10.1097/01.ju.0000180648.23405.c3.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / blood*
  • C-Reactive Protein / metabolism*
  • Carcinoma, Renal Cell / blood
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / immunology
  • Humans
  • Immunotherapy* / methods
  • Injections, Subcutaneous
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / therapeutic use*
  • Kidney Neoplasms / blood
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / immunology
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Interleukin-2
  • C-Reactive Protein